Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Terns Pharmaceuticals, Inc. Common Stock (TERN).
- Disclosed ownership: 6.8%.
- Date of event: 31 Dec 2024.
BlackRock, Inc. - 31 Dec 2024 SCHEDULE 13G/A Report for Terns Pharmaceuticals, Inc. Common Stock (TERN)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- TERN
- Shares outstanding
- 84,462,971 shares
- Disclosed Ownership
- 5,743,482 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 05 Feb 2025, 17:28:50 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 6.8% ownership in Terns Pharmaceuticals, Inc. Common Stock (TERN) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 05 Feb 2025, 17:28.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.8% | 5,743,482 | 5,632,520 | 0 | Spencer Fleming | Managing Director |